HC Wainwright Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $35.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 147.00% from the stock’s current price.

Several other analysts also recently commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday. Needham & Company LLC restated a “buy” rating and set a $14.00 target price on shares of Stoke Therapeutics in a research note on Friday, February 16th. Canaccord Genuity Group upped their target price on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, TD Cowen upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $19.63.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $14.17 on Tuesday. Stoke Therapeutics has a one year low of $3.35 and a one year high of $16.40. The company’s 50-day moving average is $5.88 and its 200 day moving average is $4.95. The company has a market capitalization of $632.69 million, a price-to-earnings ratio of -5.98 and a beta of 0.68.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the sale, the chief executive officer now owns 69,350 shares in the company, valued at approximately $423,035. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the sale, the chief executive officer now owns 69,350 shares in the company, valued at approximately $423,035. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Stephen J. Tulipano sold 4,116 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the sale, the chief financial officer now owns 20,746 shares in the company, valued at approximately $126,550.60. The disclosure for this sale can be found here. Insiders have sold 37,615 shares of company stock worth $212,852 in the last quarter. Company insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc bought a new stake in Stoke Therapeutics during the 1st quarter worth approximately $25,000. Point72 Hong Kong Ltd purchased a new stake in Stoke Therapeutics during the 1st quarter valued at approximately $27,000. Great West Life Assurance Co. Can grew its holdings in Stoke Therapeutics by 46.7% during the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after buying an additional 1,078 shares in the last quarter. UBS Group AG purchased a new stake in Stoke Therapeutics during the 3rd quarter valued at approximately $47,000. Finally, Quantbot Technologies LP grew its holdings in Stoke Therapeutics by 207.1% during the 1st quarter. Quantbot Technologies LP now owns 4,300 shares of the company’s stock valued at $90,000 after buying an additional 2,900 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.